Therapeutic area intelligence for Antifibrinolytic with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 3
Catalysts: 0
Companies: 2

Companies

EUGIA PHARMA →

Micro Labs →

Assets

EUGIA →

FDA →

Recent signals(3)

RegulatoryJuly 31, 2026

EUGIA PHARMA's Tranexamic Acid Supplement Receives FDA AP Status

EUGIA PHARMA's application for a supplement of Tranexamic Acid has received FDA approval status.

RegulatoryJuly 9, 2026

FDA Approval Status for Tranexamic Acid by Micro Labs

The FDA has granted an Abbreviated New Drug Application (ANDA) approval status for Tranexamic Acid submitted by Micro Labs.

RegulatoryJuly 7, 2026

Eugia Pharma's Tranexamic Acid Supplement Application Receives AP Status from FDA

The FDA has granted an Abbreviated New Drug Application (ANDA) AP status for Eugia Pharma's Tranexamic Acid.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.